Latest / The Well-Built Life / The Shingles Puzzle: Decrypting Postherpetic Neuralgia
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:22Speaker 1: and let's dive in. All right, let's dive into the
- 0:25Speaker 1: complexities of posturpedic neuralgia. a condition that often emerges post-shingles. So, Thomas,
- 0:33Speaker 1: what's the story behind the viral life cycle of shingles?
- 0:36Speaker 1: And how does it differ from the common myths people
- 0:39Speaker 1: have about this painful condition?
- 0:41Speaker 2: Right, and that's the crucial nuance here. Shingles caused by
- 0:45Speaker 2: the varicella zoster virus often gets mistaken for just another
- 0:49Speaker 2: round of chicken pox, but it's the reactivation of the
- 0:53Speaker 2: virus that causes the condition, Marcus. What's actually happening is
- 0:57Speaker 2: the virus hides in the dorsal root ganglion, waiting for
- 1:01Speaker 2: the right moment to wake up.
- 1:02Speaker 1: Exactly. Which brings up an interesting contradiction. Thomas, the virus
- 1:07Speaker 1: is hiding in this dormant state and can stay there
- 1:10Speaker 1: for years, sometimes decades before it reactivates. Can you explain
- 1:14Speaker 1: why the immune system can't find it, yet it continues
- 1:18Speaker 1: to cause pain?
- 1:19Speaker 2: Well, that's a great question, Rachel. The virus, in its
- 1:22Speaker 2: latent state, is very good at evading the immune system.
- 1:26Speaker 2: It doesn't replicate at a high enough level to be detected,
- 1:29Speaker 2: and it prevents the cells from committing programmed cell death
- 1:32Speaker 2: or apoptosis. It's almost like the virus has built a
- 1:36Speaker 2: fortress inside the nerve cell, making the immune system turn
- 1:40Speaker 2: a blind eye to it. But once it reactivates, it's
- 1:43Speaker 2: a whole different story.
- 1:45Speaker 1: And that's when the party starts in a painful way, right? So,
- 1:49Speaker 1: the rash and the pain come along with the reactivation,
- 1:53Speaker 1: leading to the dreaded posturpedic neuralgia. Can you elaborate on
- 1:57Speaker 1: how PHN develops and why it's so persistent?
- 2:00Speaker 2: Absolutely. PHN develops after the rash has gone away, but
- 2:05Speaker 2: the pain lingers. The damage to the sensory nerves during
- 2:08Speaker 2: the viral reactivation process is key here. The virus essentially
- 2:13Speaker 2: disrupts the inhibitory nerves that normally prevent pain signals from
- 2:17Speaker 2: reaching the brain, leading to hypersensitivity. This is why even
- 2:21Speaker 2: the slightest touch can trigger intense pain for people with penicillin.
- 2:25Speaker 1: That's wild when you look at the raw numbers. About
- 2:28Speaker 1: 10-15% of people who get shingles will develop PHN, and
- 2:34Speaker 1: the incidence rate of shingles itself is pretty high, with
- 2:38Speaker 1: about 1 in 3 people experiencing it in their lifetime.
- 2:43Speaker 1: It's not just a one-time thing. They need continuous care
- 2:48Speaker 1: and management.
- 2:48Speaker 2: And the age factor is huge. People over 50 are
- 2:52Speaker 2: at higher risk, with the risk increasing significantly as we
- 2:56Speaker 2: get older. So, it's not just a youth problem. That's
- 2:59Speaker 2: why preventive measures and vaccines like Shingrix are becoming increasingly important.
- 3:05Speaker 1: Speaking of which, Shingrix is the newer vaccine that's highly effective, right?
- 3:10Speaker 1: What's the debate around its efficacy and side effects?
- 3:13Speaker 2: Yeah, Shingrix has become the go-to vaccine, but to raise
- 3:17Speaker 2: some debate about its long-term efficacy and side effects …
- 3:20Speaker 2: Some argue that it might not provide lifelong protection, and
- 3:24Speaker 2: there are concerns about pain during administration and potential side effects. Still,
- 3:29Speaker 2: it's a major step forward compared to the older Zostavax vaccine.
- 3:33Speaker 1: And the non-pharmacological treatments are also sparking some curiosity. Mind-body
- 3:40Speaker 1: exercises and complementary therapies seem to have some merit, but
- 3:44Speaker 1: they are not widely adopted yet. It's all part of
- 3:48Speaker 1: the broader conversation about managing pain without relying on medication.
- 3:52Speaker 2: Absolutely. Moving forward, the future looks promising with new diagnostics
- 3:57Speaker 2: and treatments. But for now, the key is integrating different
- 4:01Speaker 2: approaches to manage this debilitating condition.
- 4:04Speaker 1: All right. Let's delve into the mechanisms behind the chronic
- 4:07Speaker 1: pain of posturpedic neuralgia. As we discussed, the virus becomes
- 4:12Speaker 1: latent in the dorsal root ganglion. But what exactly happens
- 4:16Speaker 1: to the sensory nerves during that time Right.
- 4:20Speaker 2: The latency period is fascinating. While the virus remains dormant,
- 4:24Speaker 2: it can cause latent state properties that make it nearly
- 4:27Speaker 2: impossible for the immune system to detect or eliminate. This
- 4:31Speaker 2: means we are talking about months or even years of latency.
- 4:34Speaker 2: And that's just the tip of the iceberg.
- 4:36Speaker 1: Exactly. And once the virus reactivates, often due to immune
- 4:40Speaker 1: system decline, it can cause significant damage to sensory nerves.
- 4:46Speaker 1: This is where the pain mechanism comes into play. Can
- 4:49Speaker 1: you elaborate on how the damage affects the nerve fibers?
- 4:52Speaker 2: Sure. Essentially, during the reactivation, the VZV can affect the
- 4:57Speaker 2: myelin sheath, leading to demyelination and functional impairment of sensory nerves.
- 5:03Speaker 2: This damage disrupts the normal pain-inhibiting processes and can lead
- 5:07Speaker 2: to hypersensitivity, making even the slightest touch or movement feel excruciating.
- 5:13Speaker 1: That's wild when you look at the raw numbers. Studies
- 5:16Speaker 1: show that up to 15% of shingles cases, can lead
- 5:19Speaker 1: to PHN. The pain can persist for years, impacting quality
- 5:24Speaker 1: of life immensely. How does this compare to the acute
- 5:28Speaker 1: pain experienced during shingles?
- 5:30Speaker 2: Well, the acute pain during shingles is often a result
- 5:33Speaker 2: of direct viral interaction with nerve fibers, similar to a
- 5:37Speaker 2: burn or a severe sting. But PHN is different. It's
- 5:41Speaker 2: the chronic pain that lingers after the rash has healed.
- 5:45Speaker 2: often causing individuals to experience intense pain from everyday activities
- 5:49Speaker 2: like putting on clothes.
- 5:50Speaker 1: And that's where the real challenge comes in. The pain
- 5:54Speaker 1: can be so severe, it can mimic other painful conditions.
- 5:58Speaker 1: How do clinicians differentiate between acute and chronic pain in
- 6:02Speaker 1: this context?
- 6:03Speaker 2: Good point. Clinicians have to rely on a combination of
- 6:07Speaker 2: symptom history, physical examination, and sometimes imaging studies. But what's
- 6:12Speaker 2: interesting is the psychological component. Stress and emotional factors can
- 6:17Speaker 2: exacerbate the pain, making it seem more intense and more debilitating.
- 6:21Speaker 1: Absolutely. And this is where mind-body exercises and complementary therapies
- 6:26Speaker 1: come in. They are starting to show some promise in
- 6:30Speaker 1: managing these symptoms. Have you seen any particularly effective practices? Yes.
- 6:36Speaker 2: Mindfulness meditation, for instance, has shown some benefits in reducing
- 6:40Speaker 2: pain perception. but it's important to integrate these practices with
- 6:44Speaker 2: traditional medical therapies for a more holistic approach. After all,
- 6:49Speaker 2: managing chronic pain isn't just about addressing the physical symptoms,
- 6:53Speaker 2: but also considering the emotional and psychological impact.
- 6:57Speaker 1: Shingles and posturpedic neuralgia, PHN, are like two different chapters
- 7:01Speaker 1: of the same story. The viral life cycle of VZV
- 7:05Speaker 1: is fascinating, but when it comes to the stakeholders and
- 7:08Speaker 1: the quantitative data points, the complexity really starts to unravel.
- 7:13Speaker 1: What do you think, Thomas? How do we see the
- 7:15Speaker 1: stakeholders involved in this narrative?
- 7:18Speaker 2: It's a layered story, Rachel. Let's start with the numbers.
- 7:23Speaker 2: The shingles vaccine, particularly Shingrix, is supposed to be highly effective,
- 7:29Speaker 2: with about 90% efficacy in preventing shingles and 56% in
- 7:34Speaker 2: preventing PHN. But Therese, a debate surrounding these figures. For instance,
- 7:40Speaker 2: to raise a subset of the elderly population, which faces
- 7:44Speaker 2: a higher risk of developing PHN, and this age-related risk
- 7:48Speaker 2: factor also needs to be factored in.
- 7:50Speaker 1: Right, exactly. The vaccine's efficacy becomes crucial in this context.
- 7:56Speaker 1: But what about the alternative treatments? Mindfulness meditation and acupuncture
- 8:01Speaker 1: have shown some benefits, yet they are often seen as
- 8:04Speaker 1: complementary rather than replacement therapies. Do you think these practices
- 8:09Speaker 1: could make a significant difference in the management of PHN?
- 8:12Speaker 2: Absolutely. They can play a valuable role. For example, acupuncture
- 8:17Speaker 2: has been shown to reduce the intensity of pain. But
- 8:20Speaker 2: it's not a one-size-fits-all solution. The key is integration. Just
- 8:25Speaker 2: as we saw in the earlier discussions, these practices need
- 8:28Speaker 2: to be part of a broader holistic approach to healing.
- 8:32Speaker 1: Indeed, the psychological and emotional impact of chronic pain can't
- 8:36Speaker 1: be underestimated. The Centers for Disease Control and Prevention, CDC,
- 8:41Speaker 1: reports that 10 to 15 percent of shingles cases develop
- 8:46Speaker 1: into PHN. That's a significant portion. The risk increases with age,
- 8:51Speaker 1: and so does the severity. Have you come across any
- 8:54Speaker 1: studies on the long-term effects of untreated PHN?
- 8:59Speaker 2: Yes, there are some. Although the research is still nascent,
- 9:03Speaker 2: untreated PHN can lead to significant reductions in quality of life.
- 9:07Speaker 2: Patients often report sleep disturbances, depression, and anxiety. The economic
- 9:12Speaker 2: burden is also substantial, with increased healthcare costs. It's a
- 9:16Speaker 2: double-edged sword. We need to focus on early intervention and
- 9:21Speaker 2: comprehensive care.
- 9:22Speaker 1: That definitely adds urgency to the conversation. Moving on, to
- 9:27Speaker 1: raise the debate around vaccine efficacy. Some argue that the
- 9:32Speaker 1: long-term benefits of the shingles vaccine might diminish over time.
- 9:38Speaker 2: The vaccine's protective effect does wane over time, which is
- 9:42Speaker 2: a critical point. Clinical trials and observational studies are ongoing
- 9:47Speaker 2: to see if booster doses might maintain long-term efficacy. The
- 9:51Speaker 2: discussion around side effects is also pertinent. While serious adverse
- 9:55Speaker 2: events are rare, the mild to moderate side effects can
- 9:58Speaker 2: be a concern for some.
- 10:00Speaker 1: True, and the patient-centric approach is essential. Integrating mental health
- 10:05Speaker 1: support into care plans could make a substantial difference. How
- 10:09Speaker 1: do you see interdisciplinary care fitting into this picture, Thomas?
- 10:14Speaker 2: Precisely, an interdisciplinary team. including primary care physicians, specialists, and
- 10:20Speaker 2: mental health professionals, forms the backbone of effective pen management.
- 10:25Speaker 2: The goal is to address both the physical and psychological
- 10:29Speaker 2: aspects of the condition. Collaboration and communication are key. For instance,
- 10:34Speaker 2: primary care providers can identify symptoms early and refer to
- 10:38Speaker 2: specialists when necessary.
- 10:40Speaker 1: Exactly. The future looks promising with advancements in diagnostic tools
- 10:44Speaker 1: and treatment options. But for now, the focus should be
- 10:48Speaker 1: on managing the condition effectively. What do you think about
- 10:51Speaker 1: the role of vitamin D in preventing PHN? It's one
- 10:55Speaker 1: of those variables that's hard to quantify.
- 10:57Speaker 2: Vitamin D is an interesting variable. Studies have shown that
- 11:01Speaker 2: deficiency might play a part in VZV latency. Supplementation could
- 11:06Speaker 2: be beneficial, but more research is needed to determine the
- 11:10Speaker 2: optimal dose and timing. For now, it's an area with
- 11:13Speaker 2: a lot of potential.
- 11:14Speaker 1: The immune system's involvement in PHN is a fascinating paradox.
- 11:19Speaker 1: It's like the virus is hiding, lying dormant, while the
- 11:23Speaker 1: immune response is often seen as trying to fight it.
- 11:26Speaker 1: But once the virus reactivates, the immune system's attempt to
- 11:30Speaker 1: control it actually contributes to the chronic pain.
- 11:33Speaker 2: Exactly. The immune system's role is a critical debate angle.
- 11:37Speaker 2: It's almost as though the body's natural defense mechanisms are
- 11:41Speaker 2: contributing to the problem, rather than solving it. Think of
- 11:45Speaker 2: it like a small fire that the body tries to smother,
- 11:48Speaker 2: but instead, it just keeps smoldering.
- 11:50Speaker 1: Right. This leads us to another topic, patient-centric care. How
- 11:55Speaker 1: do we address the psychological impact of PHN on patients?
- 11:59Speaker 1: It's more than physical pain. It's a mental and emotional
- 12:03Speaker 1: burden that can be overwhelming.
- 12:05Speaker 2: Absolutely. Patient-centered care isn't just about addressing the physical symptoms
- 12:10Speaker 2: but understanding the holistic impact. For instance, some patients might
- 12:14Speaker 2: experience heightened anxiety or depression, which can exacerbate the pain.
- 12:19Speaker 2: It's a delicate balance, but it's crucial for long-term management.
- 12:23Speaker 1: And this brings us to another interesting contradiction. The vaccines
- 12:27Speaker 1: are effective in prevention, but long-term efficacy and side effects
- 12:31Speaker 1: are still being debated. Some studies suggest the benefits might
- 12:35Speaker 1: diminish over time, while others highlight the safety and effectiveness
- 12:39Speaker 1: of the newer vaccines.
- 12:41Speaker 2: That's a good point. The debate isn't just about who
- 12:45Speaker 2: should get the vaccine, but also how long its protection lasts.
- 12:49Speaker 2: It's a tricky situation given the high incidence of developing PHN,
- 12:53Speaker 2: especially in older adults.
- 12:55Speaker 1: That's true, and the variability in treatment efficacy adds to
- 12:58Speaker 1: the complexity. We see that antiviral medications might provide short-term relief.
- 13:04Speaker 1: But managing the pain long-term often requires a multifaceted approach,
- 13:09Speaker 1: including psychological support, and possibly even complementary therapies.
- 13:14Speaker 2: Exactly. It's like trying to put out a fire with
- 13:17Speaker 2: a variety of tools. Some methods work better than others,
- 13:21Speaker 2: and a tailored approach is key. Plus, the psychological and
- 13:25Speaker 2: emotional support is just as important as the physical treatment.
- 13:29Speaker 1: And let's not forget the interdisciplinary care. Collaboration between primary
- 13:34Speaker 1: care physicians, specialists, and mental health professionals is essential. A
- 13:40Speaker 1: comprehensive team approach can help manage the condition more effectively
- 13:45Speaker 1: and improve the quality of life for patients.
- 13:48Speaker 2: Yes, it's all about integrating these different perspectives. It's an
- 13:52Speaker 2: exciting time with emerging technologies and potential new therapies on
- 13:56Speaker 2: the horizon. The future of Fencare is looking more promising,
- 14:00Speaker 2: but we still have many questions to answer. Indeed.
- 14:03Speaker 1: The journey to understanding and treating PHN is far from over,
- 14:07Speaker 1: but every step brings us closer to providing better care.
- 14:10Speaker 1: It's important to keep these discussions, going to ensure we
- 14:14Speaker 1: are doing everything we can for those living with this condition. So, Thomas,
- 14:19Speaker 1: let's talk about the emerging diagnostic tools that might revolutionize
- 14:23Speaker 1: how we manage PHN. Can you paint a picture of
- 14:27Speaker 1: what we are seeing on the horizon?
- 14:29Speaker 2: Absolutely, Rachel. There are some really exciting developments. For example,
- 14:34Speaker 2: novel immune biomarkers could provide an earlier and more precise
- 14:38Speaker 2: diagnosis of PHN. Imagine a simple blood test that could
- 14:43Speaker 2: identify specific inflammatory markers, allowing doctors to intervene much sooner
- 14:48Speaker 2: and reduce the pain from the start.
- 14:50Speaker 1: That's a game changer. And what about imaging techniques? Are
- 14:55Speaker 1: there any breakthroughs there?
- 14:56Speaker 2: Yes, exactly. MRI and PET scans are being used in
- 15:00Speaker 2: new ways to visualize nerve damage and inflammation. These high-resolution
- 15:05Speaker 2: images can pinpoint areas of damage that were previously undetectable.
- 15:09Speaker 2: This not only helps in diagnosis, but also in tailoring
- 15:12Speaker 2: treatment plans to address the specific areas affected.
- 15:15Speaker 1: Fascinating. And on the treatment side, what innovations are pushing
- 15:19Speaker 1: the boundaries of what we can do for PHN patients?
- 15:22Speaker 2: There are several promising areas. Gene therapies, for instance, could
- 15:27Speaker 2: target specific genetic expressions that contribute to pain pathways. Additionally,
- 15:33Speaker 2: immunotherapies that precisely modulate the immune response to VZV could
- 15:38Speaker 2: prevent PHN from developing in the first place. It's like
- 15:42Speaker 2: hitting the brakes on the immune system when it's going
- 15:44Speaker 2: too far.
- 15:45Speaker 1: That's wild. When you look at the raw numbers, current
- 15:48Speaker 1: treatments like antivirals and pain relief often only provide partial relief.
- 15:54Speaker 1: How do these new therapies stack up?
- 15:56Speaker 2: They show a lot of promise, but we are a
- 15:58Speaker 2: few years away from widespread use. Clinical trials are ongoing,
- 16:03Speaker 2: and the early results are encouraging. For instance, a new
- 16:06Speaker 2: class of drugs that target nerve growth factor could potentially
- 16:10Speaker 2: prevent chronic pain from developing after shingles, which is a
- 16:13Speaker 2: major breakthrough.
- 16:14Speaker 1: The shift towards integrated care models sounds like it could
- 16:17Speaker 1: really make a difference, too. Can you explain how that works?
- 16:21Speaker 1: Of course.
- 16:22Speaker 2: Integrated care models prioritize a holistic approach. Focusing not just
- 16:27Speaker 2: on the physical but also on the mental and emotional
- 16:29Speaker 2: aspects of a patient's life. This means involving not just
- 16:33Speaker 2: primary care providers but also specialists like pain management, mental
- 16:37Speaker 2: health professionals, and sometimes even complementary therapists. It's about empowering
- 16:43Speaker 2: patients to take control of their own health and well-being,
- 16:47Speaker 2: making them active participants in their care journey.
- 16:50Speaker 1: That's a shift from the more siloed practices we have
- 16:52Speaker 1: seen in the past. How do you see this playing
- 16:56Speaker 1: out in real-world settings?
- 16:57Speaker 2: It's already happening in some clinics and hospitals. For example,
- 17:02Speaker 2: some care centers are setting up multidisciplinary teams where patients
- 17:06Speaker 2: can see specialists in one visit. This streamlined approach ensures
- 17:11Speaker 2: that all aspects of their health are addressed, leading to
- 17:14Speaker 2: better outcomes. It's about creating seamless patient-centered care that addresses
- 17:20Speaker 2: their unique needs.
- 17:21Speaker 1: It sounds like these integrated models are the future. How
- 17:25Speaker 1: can we encourage more healthcare systems to adopt them?
- 17:28Speaker 2: Education and collaboration are key. We need to train healthcare
- 17:32Speaker 2: providers to see PHN as a complex condition that requires
- 17:36Speaker 2: a team approach. Also, showing the evidence that integrated care
- 17:41Speaker 2: models reduce hospitalizations and improve quality of life can be convincing.
- 17:46Speaker 2: Pilot programs and success stories can also generate interest and
- 17:50Speaker 2: support from both providers, and the public.
- 17:53Speaker 1: Well, I think it's important that we keep sharing these
- 17:56Speaker 1: ideas and promoting integrated care. Thanks for deepening our understanding
- 18:01Speaker 1: of these new possibilities, Thomas.
- 18:03Speaker 2: Absolutely, Rachel. It's an exciting time with so much potential
- 18:07Speaker 2: to improve the lives of PHN patients. Let's keep this
- 18:11Speaker 2: conversation going.
- 18:12Speaker 1: That brings us to the end of today's episode. Thank
- 18:15Speaker 1: you so much for spending part of your day with me.
- 18:18Speaker 1: If you found this episode's tips helpful and want to
- 18:20Speaker 1: make sure you don't miss the next conversation, please take
- 18:23Speaker 1: a quick second to hit that subscribe or follow button
- 18:26Speaker 1: on whatever platform you are listening on. It's a completely
- 18:29Speaker 1: free way to support the show and helps more people
- 18:32Speaker 1: find us. This podcast is independently produced, so if you
- 18:36Speaker 1: are ever in a position where you would like to
- 18:38Speaker 1: help keep it running, we do accept small donations. You
- 18:42Speaker 1: can find a link right in the episode description below
- 18:45Speaker 1: to buy us a coffee or contribute what you can.
- 18:48Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 18:53Speaker 1: and we will talk again soon.